Shares of Natus Medical Inc (NASDAQ:BABY) have received a consensus recommendation of “Hold” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $46.50.
Several analysts recently commented on the company. Zacks Investment Research upgraded Natus Medical from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. BidaskClub cut Natus Medical from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th.
In other Natus Medical news, Director William M. Moore sold 5,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $41.01, for a total transaction of $205,050.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Dong Chune Christopher Chung sold 12,642 shares of the stock in a transaction on Monday, November 6th. The shares were sold at an average price of $42.91, for a total value of $542,468.22. Following the transaction, the vice president now directly owns 141,414 shares of the company’s stock, valued at $6,068,074.74. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.
Shares of Natus Medical (NASDAQ:BABY) traded down $0.30 during trading on Monday, hitting $38.55. The stock had a trading volume of 121,772 shares, compared to its average volume of 383,084. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.21 and a quick ratio of 3.36. The firm has a market cap of $1,210.34, a PE ratio of -428.29 and a beta of 0.84. Natus Medical has a fifty-two week low of $31.65 and a fifty-two week high of $43.60.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.02. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The business had revenue of $122.60 million for the quarter, compared to analysts’ expectations of $122.41 million. During the same period in the prior year, the firm earned $0.39 EPS. The business’s quarterly revenue was up 34.9% on a year-over-year basis. research analysts forecast that Natus Medical will post 1.74 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/12/25/natus-medical-inc-baby-receives-average-rating-of-hold-from-analysts.html.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.